Literature DB >> 28496872

Atrial Fibrillation and Renal Disease.

Alexander Berkowitsch1, Maciej Wójcik2, Sergey Zaltsberg1, Dmitri Pajitnev1, Damir Erkapic3, Joern Schmitt3, Christian Hamm1, Malte Kuniss1, Thomas Neumann1.   

Abstract

Co-incidence of atrial fibrillation and renal dysfunction in general population is described in many epidemiological studies. Major issue is optimal anticoagulation in patients with atrial fibrillation and renal disease warranting balance between risks of ischemic stroke and hemorrhages. The second issue is catheter ablation of AF patients with renal dysfunction. Both issues are discussed in this paper.

Entities:  

Year:  2013        PMID： 28496872      PMCID： PMC5153230          DOI： 10.4022/jafib.837

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


  17 in total

1.  Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up.

Authors:  Yoshihisa Naruse; Hiroshi Tada; Yukio Sekiguchi; Takeshi Machino; Mahito Ozawa; Hiro Yamasaki; Miyako Igarashi; Kenji Kuroki; Yoko Itoh; Nobuyuki Murakoshi; Iwao Yamaguchi; Kazutaka Aonuma
Journal:  Heart Rhythm       Date:  2010-11-04       Impact factor: 6.343

2.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2013-05       Impact factor: 5.214

Review 3.  New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Authors:  Birgitte Klindt Poulsen; Erik Lerkevang Grove; Steen Elkjaer Husted
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

Review 4.  Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.

Authors:  Ricarda Marinigh; Deirdre A Lane; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2011-03-22       Impact factor: 24.094

5.  Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation.

Authors:  Jonathan P Piccini; Moritz F Sinner; Melissa A Greiner; Bradley G Hammill; João D Fontes; James P Daubert; Patrick T Ellinor; Adrian F Hernandez; Allan J Walkey; Susan R Heckbert; Emelia J Benjamin; Lesley H Curtis
Journal:  Circulation       Date:  2012-09-26       Impact factor: 29.690

6.  Associations between renal function, atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation.

Authors:  Tze-Fan Chao; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Kazuyoshi Suenari; Cheng-Hung Li; Shih-Ann Chen
Journal:  Circ J       Date:  2011-07-20       Impact factor: 2.993

7.  Relationship between renal function and the risk of recurrent atrial fibrillation following catheter ablation.

Authors:  Michifumi Tokuda; Teiichi Yamane; Seiichiro Matsuo; Keiichi Ito; Ryohsuke Narui; Mika Hioki; Shin-Ichi Tanigawa; Tokiko Nakane; Seigo Yamashita; Keiichi Inada; Kenri Shibayama; Satoru Miyanaga; Hiroshi Yoshida; Hidekazu Miyazaki; Taro Date; Takashi Yokoo; Michihiro Yoshimura
Journal:  Heart       Date:  2010-11-09       Impact factor: 5.994

8.  Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study.

Authors:  Hiroshi Watanabe; Toru Watanabe; Shigeru Sasaki; Kojiro Nagai; Dan M Roden; Yoshifusa Aizawa
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

Review 9.  The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?

Authors:  Manish M Sood; Paul Komenda; Amy R Sood; Claudio Rigatto; Joe Bueti
Journal:  Chest       Date:  2009-10       Impact factor: 9.410

10.  Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality.

Authors:  Kevin C Abbott; Fernando C Trespalacios; Allen J Taylor; Lawrence Y Agodoa
Journal:  BMC Nephrol       Date:  2003-01-24       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.